M&A Deal Summary

Eyevance Pharmaceuticals Acquires Focus Laboratories - FRESHKOTE

On September 11, 2018, Eyevance Pharmaceuticals acquired life science company Focus Laboratories - FRESHKOTE from Focus Laboratories

Acquisition Highlights
  • This is Eyevance Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is Eyevance Pharmaceuticals’ 1st transaction in the United States.
  • This is Eyevance Pharmaceuticals’ 1st transaction in Arkansas.

M&A Deal Summary
Date 2018-09-11
Target Focus Laboratories - FRESHKOTE
Sector Life Science
Buyer(s) Eyevance Pharmaceuticals
Sellers(s) Focus Laboratories
Deal Type Divestiture

Target

Focus Laboratories - FRESHKOTE

North Little Rock, Arkansas, United States
Focus Laboratories, Inc. - FRESHKOTE is a lubricant eye drop provider. FRESHKOTE® PF is designed to support the integrity of all three layers of the eye's tear film, offering dry eye patient's relief from their symptoms.

Search 200,291 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Eyevance Pharmaceuticals

Fort Worth, Texas, United States
Category Company
Founded 2017
Sector Life Science
DESCRIPTION

Eyevance Pharmaceuticals is committed to developing and commercializing innovative and impactful ophthalmic products that enable optimal vision, better quality of life, and address significant unmet medical needs. Eyevance Pharmaceuticals was founded in 2017 and is based in Fort Worth, Texas.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 2
State (Arkansas) 1 of 1
Country (United States) 1 of 1
Year (2018) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-10-16 Novartis AG - TOBRADEX & NATACYN

Basel, Switzerland

Novartis AG's TOBRADEX is a fixed-dose topical antibiotic and corticosteroid combination indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Novartis AG's NATACYN is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis.

Buy -

Seller(S) 1

SELLER

Focus Laboratories

North Little Rock, Arkansas, United States
Category Company
Founded 2005
Sector Life Science
DESCRIPTION

Focus Laboratories, Inc. is an eye care company dedicated to addressing the needs of healthcare providers and their patients through the discovery and development of innovative medicines and devices that support eye health and improve the quality of life. Focus Laboratories, Inc. was founded in 2005 and is based in North Little Rock, Arkansas.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Arkansas) 1 of 1
Country (United States) 1 of 1
Year (2018) 1 of 1
Mergr

Product

Company

Legal